On Oct. 21, 2021, Gilead Sciences announced that the European Commission (EC) had approved a variation to the Conditional Marketing Authorization for Vekluryﾮ (remdesivir) to include adults who do not require supplemental oxygen and were at an increased risk of progressing to severe COVID-19.

This decision followed the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.